Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05283109Phase 1Active Not Recruiting

ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

Role: lead

NCT04903795Phase 1Not Yet Recruiting

BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

Role: lead

NCT05620914Phase 2Withdrawn

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

Role: lead

NCT03927222Phase 2Terminated

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

Role: lead

NCT02366728Phase 2Completed

DC Migration Study for Newly-Diagnosed GBM

Role: lead

All 5 trials loaded